Issues related to prior authorization.
2025 · 4th Quarter (Oct 1 - Dec 31)
THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Filed by THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES).
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 20, 2026
- Income
- Not reported
- Expenses
- $1,640,000.00
- Filing UUID
- 55f3603a-a8c1-4e3c-93e4-2237e84d7b3a
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Issues related to competition in the health care marketplace.
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues relating to implementation of the No Surprises Act.
H.R. 3838/S. 2296 Pharmacy issues related to the National Defense Authorization Act, FY2026.
"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.
Literal federal measure citations: S. 1542, H.R.2214, H.R. 5378, S. 1339, S.526
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.